Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • Medical Jobs
  • Medical Matrimony
  • MD Brand Connect
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • MCI News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Aborad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • MCI News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Aborad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Neurology and Neurosurgery
  • Neurology and Neurosurgery Cases
  • Selumetinib safe...

Selumetinib safe option for treatment of inoperable plexiform neurofibromas

Medical Dialogues Editorial TeamWritten by Medical Dialogues Editorial Team Published On 2022-06-07T12:15:06+05:30  |  Updated On 2022-06-07T15:54:23+05:30
Selumetinib safe option for treatment of inoperable plexiform neurofibromas

Selumetinib is a medication that is both effective and safe for young patients having symptomatic, inoperable plexiform neurofibromas, says an article published in Neurology.AstraZeneca is developing selumetinib, a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, for the treatment of tumors associated with neurofibromatosis and other malignancies. Even though the current approval...

Selumetinib is a medication that is both effective and safe for young patients having symptomatic, inoperable plexiform neurofibromas, says an article published in Neurology.

AstraZeneca is developing selumetinib, a mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, for the treatment of tumors associated with neurofibromatosis and other malignancies. Even though the current approval of selumetinib is anticipated to reshape the planning of children with neurofibromatosis type 1 (NF1), especially those with symptomatic and inoperable plexiform neurofibromas, no critical appraisal based on the most recent studies has summarized its efficacy and safety. As a result, Jisun Hwang and colleagues undertook this research to examine the effectiveness and safety of selumetinib in children with NF1.

Up until January 28, 2021, original studies documenting the effectiveness and safety of selumetinib in patients with NF1 were found in PubMed and EMBASE. The DerSimonian–Laird technique based on random-effects modeling was used to compute the pooled objective response rates (ORRs) and disease control rates (DCRs). The proportion of adverse events (AEs) that were pooled was also computed. The evidence's quality was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation approach.

The key findings of this study were as follow:

1. Our analysis includes five trials with a total of 126 individuals.

2. The studies' evidence quality ranged from extremely poor to moderate.

3. The pooled ORR was 73.8% (95% confidence interval: 57.3%–85.5%), and the DCR was 92.5% (95% confidence interval: 66.5%–98.7%).

4. The two most prevalent adverse events (AEs) were diarrhea (63.8%, 95% CI 52.9% –73.4%) and an increase in creatine kinase levels (63.3%, 95% CI 35.6% –84.3%).

In conclusion, this study's findings clearly demonstrate the efficacy of selumetinib in symptomatic inoperable plexiform neurofibromas ; nevertheless, larger-scale randomized controlled trials are required to determine the long-term outcome of patients administered with this medicine.

Reference:

Hwang, J., Yoon, H. M., Lee, B. H., Kim, P. H., & Kim, K. W. (2022). Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1. In Neurology (Vol. 98, Issue 9, pp. e938–e946). Ovid Technologies (Wolters Kluwer Health). https://doi.org/10.1212/wnl.0000000000013296

Selumetinib plexiform neurofibromas neurology journal neurofibromatosis 
Source : Neurology
Medical Dialogues Editorial Team
Medical Dialogues Editorial Team

    Medical Dialogues consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.

    Show Full Article
    Next Story
    Similar Posts
    NO DATA FOUND

    Editorial

    Journal Club Today

    Health News Today

    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok